4th Quarter - Amendment

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$960,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 22, 2024 $860,000 Replaced
4th Quarter - Amendment (this page) Oct 21, 2024 $960,000 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

CBO modeling Drug Pricing Fiscal year 2024 Appropriations H.R. 5376, Inflation Reduction Act H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, 2024 Importation Value of Medicine

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: Executive Office of the President (EOP); Congressional Budget Office (CBO); White House Office; SENATE; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (118th), H.R. 6363 (118th)

Copyright/Patent/Trademark CPT

Antitrust Legislation Bayh-Dole Act Biopharmaceutical Intellectual Property BPCIA Compulsory licenses Data Exclusivity H.R. 5376, Inflation Reduction Act Intellectual Property Issues in Response to coronavirus Patents Reasonable Pricing Clause S. 1128, Ensuring Access to Generic Medications Act (use patents) Section 101 WTO TRIPS Waiver

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5376 (118th), S. 1128 (118th)

Health Issues HCR

21st Century Cures Act 2.0 340B Contract Pharmacy Policy 340B Drug Discount Program Accelerated Approval Alternative Funding Programs Buy American Executive Order Cancer Moonshot CBO modeling Cell, gene and radioligand therapies Co-pay accumulator programs COVID-19 Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and counterfeiting policy issues Drug shortages policy issues FDA modernization policy issues Foreign manufacturing policy issues Genetically Targeted Technologies H.R. 1613, The Drug Price Transparency in Medicaid Act H.R. 198, Drug Pricing Transparency and Accountability Act H.R. 2534, PROTECT 340B Act of 2023 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency H.R. 4822, Health Care Price Transparency Act of 2023 H.R. 5376, Inflation Reduction Act H.R. 5378, Lower Costs, More Transparency Act H.R. 5416, The Give Kids a Chance Act H.R. 830/S. 1375, HELP Co-pays Act Health industry vertical integration Inflation Reduction Act Implementation Medicaid Payment Reform Notice of Benefit Payment Parameters (NBPP) Orphan drug policy issues Outcomes based contracting/value based arrangements Patient assistance program policy issues PDUFA, BSUFA, GDUFA Pharmaceutical quality Pharmaceutical supply chain Pharmacy benefit manager policy issues Reauthorization of PAHPA S. 1131, Drug Price Transparency Act S. 1133, 340B Accountability Act S. 1246, SMART Prices Act S. 127, The Pharmacy Benefit Manager Transparency Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1542/H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act S. 1967, Patients Before Middlemen Act S. 2837, 340B Accountability Act 2021 S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3131/H.R. 5539, ORPHAN Cures Act S. 476/HR. 5567 The Maintaining Investments in New Innovations (MINI) Act S. 652/H.R. 2630, Safe Step Act S. 79/H.R. 1717, Interagency Patent Coordination and Improvement Act of 2023 Step Therapy The Medicaid VBPs for Patients (MVP) Act Transparency policy issues

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: White House Office; Food & Drug Administration (FDA); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1717 (118th), H.R. 4822 (118th), H.R. 5567 (118th), S. 1542 (118th), S. 1131 (118th), H.R. 5539 (118th), H.R. 6283 (118th), S. 3131 (118th), S. 79 (118th), H.R. 2880 (118th), S. 652 (118th), H.R. 2534 (118th), H.R. 5378 (118th), H.R. 2630 (118th), S. 2973 (118th), H.R. 2679 (118th), H.R. 5376 (118th), H.R. 5416 (118th), H.R. 830 (118th), S. 1246 (118th), S. 2837 (118th), S. 476 (118th), H.R. 3290 (118th), H.R. 198 (118th), S. 1967 (118th), S. 127 (118th), S. 1339 (118th), H.R. 1613 (118th), S. 1375 (118th), H.R. 3561 (118th), S. 1133 (118th)

Medicare/Medicaid MMM

ASP reporting policy issues CBO modeling Center for Medicare and Medicaid Innovation (CMMI) policy issues Drug Pricing H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 2666, Medicaid for VBPs for Patients (MVP) Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency H.R. 5376, Inflation Reduction Act Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicaid rebates and waiver policy issues Medicare Part A, B and D Medicare Part D Negotiations Medicare Part D Re-design and out of pocket cap Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products S. 1544/H.R. 1199, Facilitating Access to Innovative Diagnostics (FIND) Act S. 1967, Patients Before Middlemen Act S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3131/H.R. 5539, ORPHAN Cures Act S. 476/HR. 5567, The Maintaining Investments in New Innovations (MINI) Act Transparency policy issues Value-Based Purchasing (VBP) Rule

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP); White House Office; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES

Bills named: H.R. 5539 (118th), H.R. 1613 (118th), S. 2973 (118th), H.R. 5376 (118th), S. 476 (118th), S. 1967 (118th), S. 1544 (118th), H.R. 2666 (118th), H.R. 3285 (118th), H.R. 1199 (118th), S. 3131 (118th), H.R. 3561 (118th), H.R. 2880 (118th), S. 1038 (118th), H.R. 5567 (118th)

Taxation/Internal Revenue Code TAX

Orphan Drug Tax Pharmaceutical supply chain incentives R&D Amortization Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n) & 163(o)) Tax Treaties U.S. Corporate Tax

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Access to Medicines Issues Biopharmaceutical Innovation Policies Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Quality of Medicines Regulatory Cooperation Supply chain and China Task Force policy issues Tariffs Trade Policy US Swiss Trade Relations WTO IP Waiver Fiscal year 2024 Appropriations H.R. 6363, the Further Continuing Appropriations and Other Extensions Act, 2024

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: Health & Human Services, Dept of (HHS); State, Dept of (DOS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); White House Office; U.S. Trade Representative (USTR); SENATE; Commerce, Dept of (DOC)

Bills named: H.R. 6363 (118th)

Labor Issues/Antitrust/Workplace LBR

Anti-Trust Reform Federal Trade Commission's Non-Compete Clause Proposed Rule Non-competes

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Science/Technology SCI

Artificial intelligence

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
SARAH DURR —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.